ArticleExperimental physiology2026
Clinical significance and immune microenvironment association of cuproptosis-related genes in pan-cancer.
Article in Experimental physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Exploring dysregulation of cuproptosis-related genes molecular clusters and candidate biomarkers in pterygium.Scientific reports · 2026Article
- Clinical significance and immune microenvironment association of cuproptosis-related genes in pan-cancer.Experimental physiology · 2026Article
- Epigenetic regulation of cuproptosis in cancer: mechanisms, microenvironment, and therapeutic implications.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Recent studies highlight the important roles of cuproptosis in cancer cells. However, the roles of the cuproptosis-related genes (CRGs) in different cancers are still not fully understood. Comprehensive analysis was performed using open-source bioinformatic platforms to disclose the expression profiles, prognostic significance, genomic and epigenetic characteristics, immune microenvironment, and drug sensitivity of CRGs including FDX1, LIAS, LIPT1, DLD, DLAT, PDHA1, PDHB, SLC31A1, MTF1, GLS, CDKN2A, HSPA4 and ATP7B. The colon cancer samples were further obtained to verify the correlation between CDKN2A expression and immune cell infiltration by fluorescence staining. We demonstrated the expression level, methylation and the copy number variant feature, as well as the prognostic significance of CRGs in pan-cancers. The expression of CRGs, especially PDHB, LITP1, ATP7B, HSPA4 and CDKN2A, was significantly correlated with pathological stages. The genetic alteration of CRGs was explored, and CDKN2A was the most frequently altered gene with alteration rate as high as 17% in 10,953 tumour patients. In addition, we revealed a relationship to the tumour immune microenvironment (TIME) and drug resistance in pan-cancer. Moreover, CDKN2A, which was closely correlated to pan-cancer prognosis, was especially analysed including TIME alteration, genomic heterogeneity and tumour stemness. Fluorescence images of colon cancer from different patients demonstrated a positive correlation between CDKN2A expression and the number of CD45
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.